

University of Kentucky

Maxwell H. Gluck Equine Research Center Faculty Publications

Maxwell H. Gluck Equine Research Center

12-23-2019

Aminorex Identified in Horse Urine Following Consumption of *Barbarea vulgaris*; a Preliminary Report

George Maylin New York Drug Testing and Research Program

Clara Fenger Equine Integrated Medicine

Jacob Machin University of Kentucky, jacob.machin@uky.edu

Sucheta Kudrimoti University of Kentucky, kusucheta@uky.edu

Rodney Eisenberg Frontier BioPharm, LLC.

See next page for additional authors

Follow this and additional works at: https://uknowledge.uky.edu/gerc_facpub

Part of the Large or Food Animal and Equine Medicine Commons Right click to open a feedback form in a new tab to let us know how this document benefits you.

Repository Citation

Maylin, George; Fenger, Clara; Machin, Jacob; Kudrimoti, Sucheta; Eisenberg, Rodney; Green, Jonathan D.; and Tobin, Thomas, "Aminorex Identified in Horse Urine Following Consumption of *Barbarea vulgaris*; a Preliminary Report" (2019). *Maxwell H. Gluck Equine Research Center Faculty Publications*. 50. https://uknowledge.uky.edu/gerc_facpub/50

This Article is brought to you for free and open access by the Maxwell H. Gluck Equine Research Center at UKnowledge. It has been accepted for inclusion in Maxwell H. Gluck Equine Research Center Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

Aminorex Identified in Horse Urine Following Consumption of *Barbarea vulgaris*; a Preliminary Report

Digital Object Identifier (DOI) https://doi.org/10.1186/s13620-019-0153-5

Notes/Citation Information

Published in Irish Veterinary Journal, v. 72, article no. 15.

© The Author(s) 2019

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors

George Maylin, Clara Fenger, Jacob Machin, Sucheta Kudrimoti, Rodney Eisenberg, Jonathan D. Green, and Thomas Tobin

RESEARCH

Open Access

Aminorex identified in horse urine following consumption of *Barbarea vulgaris;* a preliminary report



George Maylin¹, Clara Fenger², Jacob Machin³, Sucheta Kudrimoti³, Rodney Eisenberg⁴, Jonathan Green⁵ and Thomas Tobin^{3*}

Abstract

Background: Aminorex, (RS)-5- Phenyl-4,5-dihydro-1,3-oxazol-2-amine, is an amphetamine-like anorectic and in the United States a Drug Enforcement Administration [DEA] Schedule 1 controlled substance. Aminorex in horse urine is usually present as a metabolite of Levamisole, an equine anthelmintic and immune stimulant. Recently, Aminorex identifications have been reported in horse urine with no history or evidence of Levamisole administration. Analysis of the urine samples suggested a botanical source, directing attention to the Brassicaceae plant family, with their contained GlucoBarbarin and Barbarin as possible sources of Aminorex. Since horsepersons face up to a 1 year suspension and a \$10,000.00 fine for an Aminorex identification, the existence of natural sources of Aminorex precursors in equine feedstuffs is of importance to both individual horsepersons and the industry worldwide.

Results: Testing the hypothesis that Brassicaceae plants could give rise to Aminorex identifications in equine urine we botanically identified and harvested flowering Kentucky *Barbarea vulgaris*, ("Yellow Rocket") in May 2018 in Kentucky and administered the plant orally to two horses. Analysis of post-administration urine samples yielded Aminorex, showing that consumption of Kentucky *Barbarea vulgaris* can give rise to Aminorex identifications in equine urine.

Conclusions: Aminorex has been identified in post administration urine samples from horses fed freshly harvested flowering Kentucky *Barbarea vulgaris*, colloquially "Yellow Rocket". These identifications are consistent with occasional low concentration identifications of Aminorex in equine samples submitted for drug testing. The source of these Aminorex identifications is believed to be the chemically related Barbarin, found as its precursor GlucoBarbarin in Kentucky *Barbarea vulgaris* and related Brassicaceae plants worldwide.

Keywords: Horse, Urine, Brassicaceae, Barbarea vulgaris, Aminorex, Drug testing

Background

Aminorex, (*RS*)-5-Phenyl-4,5-dihydro-1,3-oxazol-2-amine ($C_9H_{10}N_2O$, MW 162.19, Fig. 1) is an amphetamine-like anorectic and central stimulant medication and a United States Drug Enforcement Administration [DEA] Schedule 1 controlled substance. In the nineteen sixties, Aminorex was marketed as a prescription appetite suppressant in Europe but was withdrawn when it was found to be

associated with a significant incidence of cases of fatal pulmonary hypertension [1].

In the United States Aminorex began to be identified and reported as "positives" in equine samples in 2004, starting in Ohio and later in Pennsylvania and Ontario, totaling 80-plus identifications [2]. Aminorex is an Association of Racing Commissioners International [ARCI] Class 1, Penalty class A foreign substance, associated with a high potential for influencing a horse's racing performance owing to its stimulant properties. These identifications led to significant penalties against horsemen [3] but the Aminorex identifications continued, indicating that horsemen were unaware of the source of these




© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

^{*} Correspondence: ttobin@uky.edu

³The Maxwell H. Gluck Equine Research Center and Department of

Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40546, USA

Full list of author information is available at the end of the article



identifications [4]. Penalty A violations include a minimum one-year suspension absent mitigating circumstances, a minimum fine of \$10,000 (or 10% of the total purse) for the trainer as well as disqualification of the purse and placing of the horse on the Veterinarian's List for 180 days for the owner. (ARCI 2017), not insignificant penalties for a professional horseman.

Levamisole, an anthelmintic and immune stimulant used in horses and livestock, was implicated as a source of Aminorex identifications in 2007 [2]. Levamisole was originally identified as an immune modulator for horses in 1997 [5], and gained popularity as an adjunctive treatment for Equine Protozoal Myeloencephalitis over the following decade. In 2009 Ho et al. identified Levamisole metabolites, Rexamino and Compound II, and concluded that these metabolites could be co-identified with Aminorex in cases where the Aminorex identification resulted from treatment with Levamisole [6]. The association of Levamisole with Aminorex led to the classification of Levamisole by ARCI as a Class 2 Penalty Class B foreign substance.

While the identification of Levamisole as a source of Aminorex led to a sharp reduction in the number of Aminorex identifications, it has not eliminated such findings, and in North America sporadic unexplained Aminorex identifications have occasionally been reported [2]. Additionally, a number of recent Aminorex identifications have been reported in English sport horses where there was no history of Levamisole administration and no co-identifications of the expected metabolic markers of Levamisole administration [7].

These findings suggested an Aminorex source other than Levamisole and careful review of substances coidentified in these samples showed a number of plantrelated, low molecular weight nitrogenous substances. These findings and review of the botanical literature led to the suggestion that GlucoBarbarin (Fig. 1) or its hydrolysis product Barbarin contained in certain plants and originally identified in Barbarea vulgaris, the plant from which the compound Barbarin was named, might be the source of these Aminorex identifications [8]. Additionally, our English colleagues reported identification of Aminorex in at least one presumably European member of the genus Barbarea [7] in the Brassicaceae family. Based on these reports, we identified a wellknown member of the Brassicaceae family which flowers from late April to early May in Kentucky pasture, Yellow Rocket (Barbarea vulgaris, Fig. 2) and harvested this plant in flower for administration to horses, as we now report. Further, we have also synthesized and chemically purified Barbarin for use as a Certified Reference Analytical Standard and in enough quantities for equine administrations if required [9]. This reference standard was made available for use in the Aminorex related plasma and urine analyses reported in this communication.

Results

Flowering Yellow Rocket plants were harvested, cleaned, and administered to horses with pre- and postadministration blood and urine test samples collected as described in the Experimental section, below. Analyses of serum and urine samples for Aminorex and Barbarin were performed in the New York Drug Testing and Research Program Laboratory using their International Association of Standardization [ISO]-17,025 validated analytical methods. Mass Spectral data obtained for Aminorex in urine after Yellow Rocket administrations are presented in Fig. 3. The chromatogram of an 8-h urine extract scanned from 100 to 500 amu is shown in Fig. 3a. Figure 3b shows the extracted protonated ions, masses 163 and 120 which were used to identify Aminorex in the complex urine matrix of Fig. 3a. The Liquid Chromatography-



Mass Spectroscopy [LC/MS] data for the determination of Aminorex in Yellow Rocket administrations are shown in Fig. 4. The transition for Selected Ion Monitoring of Aminorex was 163.1 > 103.1. Panel A shows the chromatogram of the pre-administration urine, Panel B shows a 4-h urine

extract, Panel C shows the chromatogram of a 12-h urine extract, Panel D shows the chromatogram of an 8 h urine extract, Panel E shows a pre-administration urine extract and Panel F shows the chromatogram of the Aminorex standard. All blood samples tested negative for Aminorex,





Fig. 3 a: Chromatogram of a post-8-h Yellow Rocket administration urine extract scanned from 100 to 500 am with the Aminorex peak identified. Aminorex peak determined as such by the presence of the protonated ion of Aminorex at 163 am and the major daughter ion at 120 amu, as shown in Fig. 3b. b: The extracted protonated ions, mass 163 (Aminorex parent ion) and mass 120 (major Aminorex daughter ion) which were used to identify Aminorex in the complex urine matrix of Fig. 3a



Maylin et al. Irish Veterinary Journal (2019) 72:15

(See figure on previous page.)

Fig. 4 The 6470 Triple Quadrupole LC/MS data for the determination of Aminorex in pre- and post- Yellow Rocket administration urines. The transition for Selected Ion Monitoring of Aminorex was 163.1 > 103.1. **a** shows the chromatogram of the pre-administration urine extract, **b** shows the chromatogram of a 4 h post-administration urine extract, **c** shows the chromatogram of a 8 h post-administration urine extract, **d** shows the chromatogram of a 12 h post-administration urine extract, **e** shows the chromatogram of a pre-administration urine extract demonstrating no carry-over, and **f** shows the chromatogram of the Aminorex reference standard. No evidence for the presence of Barbarin in these post *B. vulgaris* administration blood or urine samples has been identified to date

and both blood and urine samples tested negative for Barbarin. Pre-administration urine samples were all shown to be negative for both Aminorex and Barbarin.

Discussion

The identification of Aminorex in urine samples from horses administered Barbarea vulgaris is both consistent with and supports the findings and interpretations of our English colleagues [7]. Multiple members of the Brassicaceae family, including Barbarea vulgaris, produce Gluco-Barbarin, which may be responsible for ongoing sporadic Aminorex identifications reported in post-event equine urine samples in the absence of evidence of Levamisole administration. At this time, the precise mechanism for the conversion of Barbarin to Aminorex is unclear, and it is possible that some other compound produced by Barbarea vulgaris is responsible. However, based on the substantial structural similarities between Aminorex and Barbarin, Barbarin is at this time the most likely candidate for the primary source of Aminorex in the Brassicaceae family.

The role of GlucoBarbarin in Brassicaceae is to serve as a Barbarin precursor. When the plant is damaged, the co-located enzyme, myrosinase, hydrolytically removes the glucose molecule from GlucoBarbarin yielding an intermediate which spontaneously cyclizes to Barbarin. GlucoBarbarin then may act like other glucosinolates in protecting the plant from potential predators [10]. Consistent with this protective function of Barbarin, the Yellow Rocket plant material was refused by the experimental horses until mixed with grass and sweet feed.


These findings are of practical significance for horse racing regulation [11], in that there are now two innocent, inadvertent, and completely unrelated sources of Aminorex identifications in post-race urine samples. The first innocent source is Levamisole, as a result of inadvertent transfer of Levamisole from its use as an anthelmintic or as an immune modulator, commonly recommended as a component of treatment for Equine Protozoal Myeloencephalitis. The second innocent source would be, as reported here, exposure to Aminorex and/or Aminorex precursors associated with inadvertent inclusion of plant fragments of the Brassicaceae family in equine feedstuffs and their subsequent ingestion by horses about to race.

Aminorex identifications in post-race urines following Levamisole administration may be confidently identified as Levamisole related if other post-Levamisole administration metabolites, Rexamino and Compound II, described by Ho et al. [12] are identified in the sample. The inability to identify these other Levamisole metabolites in the English sport horse samples initiated an investigation for other likely sources of Aminorex, leading to identification of the Brassicaceae as a likely source of post-race trace Aminorex identifications [7].

Based on the wide distribution of *Barbarea vulgaris* in North America [Fig. 5] and the high level of sensitivity of post-race testing, it seems likely that a background level of sporadic inadvertent Aminorex identifications will be ongoing in American racing. One approach to addressing this issue is to identify biomarkers of exposure to Brassicaceae plants, which would allow confident identification of Brassicaceae as the source of these Aminorex identifications. At this time Barbarin, as has recently been synthesized and certified by our research program [9] would appear to be the first biomarker candidate for this role, but further research on administration of Brassicaceae and Barbarin itself to equines is likely required in this area.

A limitation of this research is that, given the worldwide distribution of Brassicaceae, we cannot at this time identify the geographic extent of this potential problem. A further concern is that the pharmacological significance of low concentration urinary Aminorex identifications is unclear. Based on the behavioral observations of Soma et al. [3] it seems that plasma concentrations of Aminorex must be at least 2 ng/mL for pharmacological effect. In fact, the brief five-minute duration of the pharmacological responses to IV administration of 15 mg of Aminorex reported by Soma et al. [3] suggests that these pharmacological responses are transient local high CNS concentration bolus responses, followed immediately by complete loss of pharmacological effect. Consistent with this interpretation, oral 15 mg administration of Aminorex produced no observable pharmacological responses. Given the fact that this orally ineffective dose produced urinary concentrations of Aminorex averaging about 75 ng/mL, it seems reasonable to suggest that urinary concentrations of Aminorex less than 75 ng/mL are unlikely to be associated with pharmacological effects.

With respect to identifying a Screening Limit of Detection (SLOD) for Aminorex in post-race urines, a cut-off / SLOD should be *"high enough to cut-off the environmental*



noise and low enough to stop performance enhancement" as described in [15]. Given that a sequence of five urinary Aminorex identifications of unknown origins in Massachusetts during 2017 were all less than 20 ng/mL it would seem reasonable to set a urinary interim Screening Limit of Detection of 30 ng/mL (Fenger, personal communication, July 2019), in the absence of a significant number of data points on which to base a more complete analysis.

In presenting this interim 30 ng/mL SLOD we particularly note the unusually long terminal plasma half-life of Aminorex, 46.6 h in one horse in the Soma study. This terminal plasma half-life means that individual horses exposed to an ongoing dietary source of Barbarin will accumulate urinary concentrations over a nine-to-tenday period, increasing the probability of attaining detectable urinary concentrations of Aminorex. Given this circumstance, it is important that reported Aminorex identifications include best good faith estimates of the concentrations of Aminorex identified. These data will allow evaluation of the contributions of geographically different environmental sources to urinary Aminorex identifications and the above interim Screen Limit of Detection can be adjusted if required, following the model presented by [16].

Other species within the Brassicaceae family may be similarly implicated as likely candidates for the introduction of GlucoBarbarin/Barbarin to animals. The plant *Reseda luteola*, more commonly known as "weld" or Dyer's Rocket is similarly known to produce GlucoBarbarin [17]. This plant is widely distributed throughout Europe and has been introduced to many parts of the United States. Historically used as a source of yellow dye, it was also grown domestically for its sweet aromatic smell. Based on the results herein reported with respect to *Barbarea* *vulgaris* it is reasonable to assume that if *Reseda luteola* were to be ingested a measurable level of Aminorex might also be detectable in equine urine.

Conclusion

In conclusion, oral administration of Barbarea vulgaris / Yellow Rocket plant material to two horses has resulted in urinary Aminorex identifications. The proximate chemical source of these Aminorex identifications is likely to be GlucoBarbarin/Barbarin, long-recognized components of the Yellow Rocket plant. Given these circumstances and the widespread distribution of such plants in North America and elsewhere, Yellow Rocket or related Brassicaceae plants are likely sources of sporadic low-concentration Aminorex identifications in the sports horse worldwide. Future research will focus on identifying biomarkers of Yellow Rocket or other Brassicaceae to definitively identify botanical origins for Aminorex identifications and the acquisition of enough field data to support or appropriately adjust our proposed 30 ng/mL environmental "cut-off" or Screening Limit of Detection (SLOD) for pharmacologically and forensically insignificant Aminorex identifications in equine drug testing.

Methods

Yellow rocket identification and harvest

Barbarea vulgaris plants in bloom were harvested from a central Kentucky pasture in mid-May, 2018, with the landowner's consent and consistent with State of Kentucky plant harvesting regulations. The harvest plants were identified as Barbarea vulgaris / Yellow Rocket by Dr. J. D. Green of the Department of Plant and Soil Sciences of the University of Kentucky. Briefly, stems were ribbed and hairless with shiny dark leaves located in basal rosettes. Basal leaves were stalked with a large terminal lobe and smaller lower lobes. All leaves were alternate with wavy and toothed margins. The flowers were present in terminal clusters above the foliage. The identified plants were cleaned of extraneous material and shipped overnight to the New York State Drug Testing and Research Program for equine administration and forensic analysis and equine administration.

Animal administration and sample collection procedures

The entire plant, including roots, leaves, stems and flowers were ground to a fine texture in an Oster Total Prep 10-C Food Processor. A total of 0.45 kg of wet weight processed plant material was presented to each of two horses. *Barbarea vulgaris* plant material was refused by the horses when presented alone but was readily consumed when mixed with an equivalent amount of sweet feed and fresh cut grass. Blood and urine samples were collected as preadministration zero-time samples and then at 4, 8, and 12 h post administration.

Mature Standardbred mares weighing between 400 and 540 kg and aged 8 and 11 years were used for these administration experiments. These horses were part of the New York State Drug Testing and Research Program research herd and were in good health and monitored by experienced veterinary clinicians. Mares were maintained in their home box stalls and all sample collections and substance administrations were performed in their home stalls. Blood samples were collected by jugular venipuncture and urine samples by bladder catheterization and draining of the bladder at the indicated time intervals, as previously described [18]. Blood samples were allowed to clot, then centrifuged at 1500 g for 10 m and the serum decanted and stored at -20 °C until analysis. Urine samples were similarly aliquoted, sealed, and stored at -20 °C until analysis. All physical analyses occurred within 20 days of collection. All samples were collected under the supervision of New York State Drug Testing and Research Program personnel and transferred to the New York State Drug Testing and Research Program laboratory where they were logged in as dated and numbered research samples.

Extraction

Aminorex was extracted from 4.0 ml urine samples adjusted with pH 9.5 carbonate buffer using 4.0 ml of ethyl acetate/hexane solvent (9: 1 v/v). The samples were mixed on a rotary mixer and centrifuged for 1 0 min each. The organic phases were transferred to concentration tubes and evaporated to dryness in a 50 °C water bath under nitrogen flow. The residues were reconstituted in methanol for LC/MS analysis.

Liquid chromatography/mass spectrometry

An Agilent Technologies 6150 B Quadrupole LC/MS System and an Agilent 64 70 Triple Quadrupole LC/MS System in positive ionization modes were used for screening and confirmatory analysis respectively. Each instrument used 1290 Infinity Auto Injectors and thermostated column compartments. The 6150B used an Agilent Eclipse AAA, 3 × 100 mm liquid chromatography column. The LC gradient consisted of 100% A (100%/0.1% formic acid) for 5 min and then a linear gradient to 100% B (90% methanol/10% 0.1 formic acid) at 20 min at a flow of 0.4 mL/minute. Column compartment was 40 °C. The 6470 Triple Quadrupole used an Agilent Poroshell EC-120, 3.0 × 100 LC column. An LC gradient of acetonitrile/formic acid in the following composition was used: (90% formic acid/10% acetonitrile) for 1 m, (5% formic acid/95% acetonitrile) for 4.5 min and (90% formic acid/10% acetonitrile) at 5 min. Flow rate was 0.4 ml/minute and column temperature was 50 °C. Limit of Detection was 1 ng/mL and urinary concentrations of Aminorex were estimated to be approximately in the range of 10 ng/ml. No Aminorex

was detected in the post-administration plasma samples, and no Barbarin was detected in either the plasma or urine samples.

Abbreviations

ARCI: Association of Racing Commissioners International; DEA: Drug Enforcement Administration (USA); IACUC: Institutional Animal Care and Use Committee; ISO: International Organization for Standardization; LC/MS: Liquid Chromatography/Mass Spectroscopy; SLOD: Screening Limit of Detection

Acknowledgements

Published as paper #499 from T Tobin and the Equine Pharmacology, Therapeutics and Toxicology Program at the Maxwell H. Gluck Equine Research Center and Department of Veterinary Science, University of Kentucky. The information reported in this paper is part of a project of the Kentucky Agricultural Experiment Station (KAES publication #18-01-068) and is published with the approval of the Director. This research was supported by grants from the USDA Agriculture Research Service Specific Cooperative Agreement #58-6401-2-0025 for Forage-Animal Production Research, the Kentucky Department of Agriculture, and the Kentucky Thoroughbred Association Foundation and by support for the Kentucky Agricultural Experiment Station as provided by the National Institute of Food and Agriculture (NIFA) and the Commonwealth of Kentucky. Other support that made this work possible includes research support from The National Horsemen's Benevolent and Protective Association and the Alabama, Arizona, Arkansas, Ontario, Canada; Charles Town, WV; Florida, Indiana, Iowa, Kentucky, Louisiana, Michigan, Minnesota, Nebraska, Ohio, Oklahoma, Oregon, Pennsylvania, Tampa Bay Downs, Florida, Texas, Washington State, and West Virginia Horsemen's Benevolent and Protective Associations, Equine Health and Welfare Alliance, Inc., and Mrs. John Hay Whitney.

Authors' contributions

Pasture sources of Kentucky Yellow Rocket were identified by CF and JM, who identified and collected the *B. vulgaris* plant material growing in Kentucky for this research project. The collected samples were positively identified as *B. vulgaris* by JDG and processed, dried and shipped to GM who administered them to the test horses and analyzed the blood and urine samples for Barbarin and Aminorex. Certified reference standard Barbarin for the analytical work was synthesized, analytically characterized and certified by JM, SK and RE and provided to GM as a reference standard. JM, SK, and RE, GM and TT verified data from the synthetic and analytical chemistry work. All authors contributed scientific experimental design, data interpretation, figure preparation, and the writing and editing of the manuscript and all authors approved the final manuscript submitted for publication.

Funding

Funding sources are as noted in the Acknowledgements section. Funding sources provided no role in the design of the study, nor in the collection, analysis, and interpretation of the data and writing of the manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Animal administration was approved via Institutional Animal Care and Use Committee [IACUC] Protocol Number EHWA0818, as filed by Dr. Clara Fenger at Equine Integrated Medicine, 4904 Ironworks Rd., Georgetown, KY.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author details

¹New York Drug Testing and Research Program, 777 Warren Rd, Ithaca, NY 14853, USA. ²Equine Integrated Medicine, 4904 Ironworks Rd, Georgetown, KY 40324, USA. ³The Maxwell H. Gluck Equine Research Center and Department of Toxicology and Cancer Biology, University of Kentucky,

Received: 10 June 2019 Accepted: 22 November 2019 Published online: 23 December 2019

References

- Poos GI, Carson JR, Rosenau JD, et al. 2-Amino-5-aryl-2-oxazolines. Potent new anorectic agents. J Med Chem. 1963;6:266–72.
- Gutierrez J, Eisenberg RL, Koval NJ, Armstrong ER, Tharappel J, Hughes CG, Tobin T. Pemoline and Tetramisole 'positives' in English racehorses following Levamisole administration. Ir Vet J. 2010;63(8):498.
- Soma LR, Rudy JA, Udoh CE, Xu F, Snapp HM. Pharmacokinetics and effects of Aminorex in horses. Am J Vet Res. 2008;69(5):675–81.
- Barker SA. The formation of Aminorex in racehorses following Levamisole administration. A quantitative and chiral analysis following synthetic Aminorex or Levamisole administration vs. Aminorex-positive samples from the field: a preliminary report. J Vet Pharmacol Ther. 2009;32(2):160–6.
- Britt B, Boyars TD. Antimicrobial drugs used by veterinarians. Proc Annu Convent AAEP. 1997;43:170–7.
- Loganathan D, Fu D, Zhao S, Kwan R, Chen E, Morrissey B. Occurrence of Aminorex and Levamisole in Canadian racing part 2: comparison of Levamisole and Aminorex metabolism and elimination profiles in the horse. In: Proceedings of the 17th international conference of racing analysis and veterinarians. Antalya; 2009. p. 204–13. R&W Communications
- Teale P, Biddle S. Possible plant sources of Aminorex and potential markers of their ingestion in the horse. Presented at *Proceedings of the 22nd International Conference of Racing Analysists and Veterinarians*. Dubai; 2018.
 p. 100. Abstracts Volume. Currently awaiting publication.
- Kjær A, Gmelin R. IsoThiocyanates. XXVII. A new isoThyiocyanate Glucoside (GlucoBarbarin) furnishing (–)-5-Phenyl-2-oxazolidinethione upon Enzymic hydrolysis. L. Acta Chem Scand. 1957;11:906–7. https://doi.org/10.3891/acta. chem.scand.11-0906.
- Machin J, Kudrimoti S, Eisenberg R, Fenger C, Hartmann P, Maylin G, Tobin T, Shults T. "Synthesis, characterization and certification of Barbarin, a possible botanical source of Aminorex identifications". Submitted for presentation and publication, the Society of Forensic Toxicology (SOFT) annual meeting, Oct 07–12, 2018. Minneapolis; 2018.
- 10. Furlan L, et al. The efficacy of biofumigant meals and plants to control wireworm populations. Ind Crop Prod. 2010;31(2):245–54.
- 11. Tobin, T. (1981). Drugs and the Performance Horse. Springfield, IL: Charles C Thomas Pub Ltd.
- Ho ENM, Leung DKK, Leung GNW, Wan TSM, Wong ASY, Wong CHF, et al. Aminorex and rexamino as metabolites of Levamisole in the horse. Anal Chim Acta. 2009;638(1):58–68.
- USDA. "Plants Profile for Barbarea vulgaris." Plants Profile for Barbarea vulgaris (Yellow Rocket), United States Department of Agriculture, plants. usda.gov/core/profile? Symbol. Accessed May 24, 2018.
- 14. Botanical Society of Britain & Ireland. "Online Atlas of the British and Irish Flora for *Barbarea vulgaris*" (August 7, 2019). Online Atlas of the British and Irish Flora. Retrieved from https://www.brc.ac.uk/plantatlas/plant/barbarea-vulgaris on 16 May, 2019.
- Brewer K, Shults TF, Machin J, Kudrimoti S, Eisenberg RL, Hartman P, Tobin T. A cluster of trace-concentration methamphetamine identifications in racehorses associated with a methamphetamine-contaminated horse trailer: a report and analysis. Can Vet J. 2016;57(8):860.
- Machin J, Brewer K, Catignani M, Shults TF, Fenger C, Maylin GA, Tobin T. Review and analysis of an interim screening limit of detection for naproxen in post-race samples: accepted for publication. Comparative Exercise Physiology Sept 2, 2019; 2019.
- Kjær A, Gmelin R. IsoThiocyanates. XXXIII. An isoThyiocyanate Glucoside (GlucoBarbarin) of Reseda luteola L. Acta Chem Scand. 1958;12:1693–4. https://doi.org/10.3891/acta.chem.scand.12-1693.
- Tobin T, Blake JW. The pharmacology of procaine in the horse V. Relationships between plasma and urinary concentrations of procaine. J Equine Med Surg. 1977;1:118–94.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.